The choice of antipsychotics in schizophrenia

In light of claims of improved efficacy and lower incidence of adverse effects compared with older drugs, second-generation antipsychotics have emerged as the predominant treatment for

schizophrenia. A new meta-analysis concludes that the difference in efficacy between newer and older agents is small, and the current classification scheme for antipsychotics does not

survive close scrutiny. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support REFERENCES * Leucht, S. _ et al_. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. _Lancet_ 373, 31–41 (2009).

Article  CAS  Google Scholar  * Gründer, G., Hippius, H. & Carlsson, A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. _Nat. Rev. Drug Discov._ 8,

197–202 (2009). Article  Google Scholar  * Lieberman, J. A. _ et al_. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. _N. Engl. J. Med._ 353, 1209–1223 (2005).

Article  CAS  Google Scholar  * McEvoy, J. P. _ et al_. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond

to prior atypical antipsychotic treatment. _Am. J. Psychiatry_ 163, 600–610 (2006). Article  Google Scholar  * Leucht, S. _ et al_. A meta-analysis of head-to-head comparisons of

second-generation antipsychotics in the treatment of schizophrenia. _Am. J. Psychiatry_ 166, 152–163 (2009). Article  Google Scholar  * Rosenheck, R. _ et al_. Effectiveness and cost of

olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. _JAMA_ 290, 2693–2702 (2003). Article  CAS  Google Scholar  * Jones, P. B. _ et al_. Randomized

controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study

(CUtLASS 1). _Arch. Gen. Psychiatry_ 63, 1079–1087 (2006). Article  CAS  Google Scholar  * Carpenter, W. T. & Buchanan, R. W. Lessons to take home from CATIE. _Psychiatr. Serv._ 59,

523–525 (2008). Article  Google Scholar  * Ross, C. A., Margolis, R. L., Reading, S. A., Pletnikov, M. & Coyle, J. T. Neurobiology of schizophrenia. _Neuron_ 52, 139–153 (2006). Article

  CAS  Google Scholar  Download references AUTHOR INFORMATION Author notes * R. L. MargolisJohns Hopkins Schizophrenia Program, Department of Psychiatry, Johns Hopkins University School of

Medicine, CMSC 8–121, 600 N. Wolfe Street, Baltimore, MD 21287, USA rmargoli@jhmi.edu AUTHORS AND AFFILIATIONS * Department of Psychiatry, Johns Hopkins University School of Medicine,

Baltimore, MD, USA Russell L. Margolis Authors * Russell L. Margolis View author publications You can also search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING

INTERESTS R. L. Margolis is a consultant for AstraZeneca. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Margolis, R. The choice of antipsychotics in

schizophrenia. _Nat Rev Neurol_ 5, 308–310 (2009). https://doi.org/10.1038/nrneurol.2009.68 Download citation * Issue Date: June 2009 * DOI: https://doi.org/10.1038/nrneurol.2009.68 SHARE

THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative